false
English
Catalog
2021 World Conference on Lung Cancer (Posters)
FP09. Impact of Brain Metastasis Status on Adverse ...
FP09. Impact of Brain Metastasis Status on Adverse Events (AEs) Requiring Dose Reduction Among Patients Receiving Lorlatinib
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The study conducted a retrospective review of 130 patients who received lorlatinib for ALK-positive and ROS1-positive non-small cell lung cancers. The impact of brain metastasis on adverse events requiring dose reduction was explored. Out of the total study population, 82% had pretreatment brain metastasis. Cognitive effects, mood effects, and speech effects were the most common adverse events requiring dose reduction in patients with brain metastasis. However, there were no statistically significant differences when comparing the frequency of adverse events between patients with and without brain metastasis. Dose reductions occurred early for both groups. Further research is needed to understand the mechanisms of CNS adverse events in lorlatinib treatment.
Asset Subtitle
John F Murphy
Meta Tag
Speaker
John F Murphy
Topic
Novel Therapeutics and Targeted Therapies
Keywords
retrospective review
lorlatinib
ALK-positive
ROS1-positive
non-small cell lung cancers
×
Please select your language
1
English
5
普通话
11
Dutch